Skip to main content

Atrophic Vaginitis News (Page 2)

Related terms: Vaginal Atrophy

FDA Approves Osphena (ospemifene) for Moderate to Severe Vaginal Dryness Due to Menopause

BLAINVILLE, QC, January 29, 2019 – Duchesnay Inc., a pharmaceutical company specializing in women’s health, announced today that the FDA has approved its supplemental New Drug Application (sNDA) see...

TherapeuticsMD Announces FDA Approval of Imvexxy (estradiol vaginal inserts) for the Treatment of Dyspareunia Due to Menopause

BOCA RATON, Fla., May 30, 2018 /PRNewswire/ – TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the United States Food and Drug Administration (FDA)...

FDA Approves Osphena for Postmenopausal Women Experiencing Dyspareunia

February 26, 2013 – The U.S. Food and Drug Administration today approved Osphena (ospemifene) to treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom...

FDA Approves 10 mcg Dose of Vagifem for the Treatment of Atrophic Vaginitis Due to Menopause

PRINCETON, N.J., Dec. 2 /PRNewswire-FirstCall/ – Novo Nordisk said today that the U.S. Food and Drug Administration (FDA) has approved a 10 mcg dose formulation of Vagifem (estradiol vaginal...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Postmenopausal Symptoms

Related drug support groups

Estrace Vaginal Cream, estradiol, Vagifem, Premarin, Estrace